1. Home
  2. PPBT vs CERO Comparison

PPBT vs CERO Comparison

Compare PPBT & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPBT
  • CERO
  • Stock Information
  • Founded
  • PPBT 2010
  • CERO 2017
  • Country
  • PPBT Israel
  • CERO United States
  • Employees
  • PPBT N/A
  • CERO N/A
  • Industry
  • PPBT Biotechnology: Pharmaceutical Preparations
  • CERO
  • Sector
  • PPBT Health Care
  • CERO
  • Exchange
  • PPBT Nasdaq
  • CERO Nasdaq
  • Market Cap
  • PPBT 6.3M
  • CERO 3.5M
  • IPO Year
  • PPBT N/A
  • CERO N/A
  • Fundamental
  • Price
  • PPBT $2.49
  • CERO $9.41
  • Analyst Decision
  • PPBT Strong Buy
  • CERO Strong Buy
  • Analyst Count
  • PPBT 1
  • CERO 2
  • Target Price
  • PPBT $33.00
  • CERO $45.00
  • AVG Volume (30 Days)
  • PPBT 22.4K
  • CERO 3.3M
  • Earning Date
  • PPBT 08-15-2025
  • CERO 08-13-2025
  • Dividend Yield
  • PPBT N/A
  • CERO N/A
  • EPS Growth
  • PPBT N/A
  • CERO N/A
  • EPS
  • PPBT N/A
  • CERO N/A
  • Revenue
  • PPBT N/A
  • CERO N/A
  • Revenue This Year
  • PPBT N/A
  • CERO N/A
  • Revenue Next Year
  • PPBT N/A
  • CERO N/A
  • P/E Ratio
  • PPBT N/A
  • CERO N/A
  • Revenue Growth
  • PPBT N/A
  • CERO N/A
  • 52 Week Low
  • PPBT $2.00
  • CERO $6.71
  • 52 Week High
  • PPBT $13.95
  • CERO $895.40
  • Technical
  • Relative Strength Index (RSI)
  • PPBT 52.01
  • CERO 47.59
  • Support Level
  • PPBT $2.26
  • CERO $9.10
  • Resistance Level
  • PPBT $2.50
  • CERO $9.73
  • Average True Range (ATR)
  • PPBT 0.13
  • CERO 2.72
  • MACD
  • PPBT 0.00
  • CERO 0.09
  • Stochastic Oscillator
  • PPBT 58.82
  • CERO 13.44

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Share on Social Networks: